H&M wants to make clothing from CO2 using this startup’s tech

Rubi raised $7.5M to build a demonstration-scale cellulosic production system and has secured more than $60M in non-binding off-take agreements. The enzyme-based process — enhanced with AI/ML — aims to produce tens of tons of cellulose from captured CO2 in shipping-container-sized reactors and has been piloted with 15 partners including H&M, Patagonia, and Walmart. If commercialized at scale, the platform could displace tree-derived cellulose, shorten long textile supply chains, and offer a low-cost input for apparel and other cellulose-using industries.

Analysis

The emergence of enzyme-first cellulosic platforms is a convex technological risk to incumbent upstream pulp and timber assets: if unit economics move from pilot to industrial scale within 2–5 years, demand for virgin wood pulp could structurally compress and reorder fibre input costs for apparel and nonwoven industries. That shift will not be linear — expect a multi-year bifurcation where specialty, textile-grade cellulose commands a premium during transition while commodity pulp faces shorter-term oversupply pressure as converters chase lower-cost feedstocks.

A second-order winner set will be entities that can lock supply optionality and internalize adoption (large retailers, brands with private-label control, and companies running large-scale procurement teams). Early contracting and certification (LCA, product standards) will create capture points: a handful of offtake partners could secure multi-year spreads versus spot pulp prices, creating durable margin improvements for private-label apparel if they move quickly.

Tech enablers and platform providers (AI-guided enzyme discovery, continuous bioreactor OEMs, and downstream fiber finishing tech) represent a modular value chain where margins accrue to IP owners rather than commodity producers. The main reversal risks — enzyme deactivation at scale, unanticipated capex for continuous processing, or regulatory/certification delays — are binary and concentrated in a 12–48 month window; if they fail, incumbent pulp demand reasserts itself quickly, re-pricing winners and penalizing early equity holders.

From a macro angle, a successful scale-up reduces fossil-feedstock demand for fiber substitution and creates tension with petrochemical-linked polymer producers; this creates a staggered, sectoral rebalancing rather than an immediate collapse in related commodity markets. Monitor certification milestones, pilot-to-demo capacity announcements, and multi-year commercial offtakes as primary catalysts that move equity valuations across the supply chain.

Key Decisions for Investors

• WMT — 12-month overweight (1–2% incremental portfolio weight). Rationale: retailers that can contract low-carbon cellulosic supply early capture a margin/branding wedge; asymmetric upside if they convert private-label SKUs. Risk: adoption delays or higher cost pass-through reduce consumer demand; target 2:1 upside/downside on incremental exposure.
• IP / RYN (pair) — short pulp/timber producers vs long selective retailers (pair trade) over 12–36 months. Rationale: industrial-scale cellulosic supply would compress commodity pulp prices; short exposure sized to 0.5–1% NAV with a 20–40% downside scenario. Hedge: keep position duration to 36 months and monitor pulp spot indices and certification progress; stop-loss at 15% adverse move.
• DHR — 12–24 month long (buy-and-hold). Rationale: life-science tools and automation firms are indirect beneficiaries of faster enzyme optimization and scale-up; revenue correlation is higher and less binary than startups. Risk/reward: modest downside if biotech capex slows, 3:1 upside/downside over the horizon given secular instrument demand.
• Event-driven options play — buy 9–18 month calls on a selected large retail/consumer name (WMT) sized as a directional ticket and hedge by selling calls on a pulp-exposed name (IP) to finance premium. Rationale: asymmetric payoff around certification/offtake milestones; adjust strike widths to cap premium outlay. Risk: options expire worthless if catalysts slip beyond the term—limit allocation to <0.5% NAV.